Source Institute of Molecular Biotechnology (IMBA) Using an unbiased labeling technique, mathematical modeling, and single cell profiling to trace the footsteps of stem cells and their daughters, researchers at the University of Cambridge (UK), DGIST (S.Korea), and IMBA (Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Austria) have confirmed that two populations of
Source https://www.liebertpub.com/doi/pdf/10.1089/hum.2019.026#utm_source=ETOC&utm_medium=email&utm_campaign=hum Corneal diseases are among the most prevalent causes of blindness worldwide. The transparency and clarity of the cornea are guaranteed by a delicate physiological, anatomic, and functional balance. For this reason, all the disorders, including those of genetic origin, that compromise this state of harmony can lead to opacity and eventually vision loss.
Gilead Sciences and Galapagos announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). “We are excited about the validation of this application which is an important
Researchers from the Karolinska Institutet in Sweden have discovered a new nociceptive glio-neural complex that may only be skin deep. You’ve most likely quickly pulled your hand away when you’ve pricked it on a thorn bush, or if you fingertips get too close to fire. This is a natural reaction and generally means that your
Source STAT Rapid advances in the development of medical devices in the 21st century are contributing to healthier lives, but bring with them a new challenge: teaching clinicians how to use these often-complicated technologies. Teaching them poorly, or failing to do it at all, can negate the potential benefits and put patients at risk of
Source The Lancet. Oncology, ISSN: 1474-5488, Vol: 20, Issue: 8, Page: e443-e451 Chimeric antigen receptor (CAR) T-cell therapy is one of the most remarkable advances in cancer therapy in the last several decades. More than 300 adoptive T-cell therapy trials are ongoing, which is a testament to the early success and hope engendered by this
New research has observed that the benefits of CAR-T cell immunotherapies – for the treatment of diseases such as pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma – may be offset by their delayed delivery to patients. The social value of a therapy balances manufacturer costs and profits versus a patient’s improvement in quality-adjusted
The vision is ambitious : Enroll 1 million people in the NIH’s All of Us Research program, whose goal is to make personalized medicine a reality for everyone. That means ensuring that more than half of participants come from communities historically underrepresented in biomedical research. A year after its launch, 230,000 people have joined, 80% of
Countries that relax regulations for regenerative medicines could be causing a downward spiral in international standards, according to new research published today. Researchers warn that if just one country decides to relax regulations in the field, a heightened sense of competition can spur others to do the same. It’s unclear whether this deregulation best serves
It has taken some time in finally getting its official launch, but government has opened the doors to a new public-private research hub aimed at using new digital technologies to build products and services to help keep elderly people in their own homes for longer. The Research Hub for Digital Enhanced Living being housed at Deakin University aims
